Level Biotechnology (ROCO:3118) Cyclically Adjusted Revenue per Share: NT$23.63 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:3118 Level Biotechnology Inc ROCO:3118
76 GF Score
Price NT$32.10
GF Value NT$33.87
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Level Biotechnology Cyclically Adjusted Revenue per Share?

Level Biotechnology ROCO:3118 +0.31% 76 Cyclically Adjusted Revenue per Share is NT$23.63 as of Mar. 2026. GuruFocus rates ROCO:3118 with a GF Score™ of 76/100 and a GF Value™ of NT$33.87 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Level Biotechnology's adjusted revenue per share for the three months ended in Mar. 2026 was NT$4.869. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$23.63 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Level Biotechnology's average Cyclically Adjusted Revenue Growth Rate was 3.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Level Biotechnology was 5.80% per year. The lowest was 3.00% per year. And the median was 4.80% per year.

As of today (2026-08-12), Level Biotechnology's current stock price is NT$32.10. Level Biotechnology's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$23.63. Level Biotechnology's Cyclically Adjusted PS Ratio of today is 1.36.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Level Biotechnology was 2.09. The lowest was 1.18. And the median was 1.45.


Level Biotechnology  (ROCO:3118) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Level Biotechnology's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=32.10/23.63
=1.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Level Biotechnology was 2.09. The lowest was 1.18. And the median was 1.45.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Level Biotechnology Cyclically Adjusted Revenue per Share Related Terms


Level Biotechnology Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Level Biotechnology's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Level Biotechnology Cyclically Adjusted Revenue per Share Chart

Level Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.97 21.22 21.82 22.53 23.21

Level Biotechnology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.91 23.06 23.27 23.21 23.63

ROCO:3118 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Level Biotechnology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Level Biotechnology Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Level Biotechnology's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Level Biotechnology's Cyclically Adjusted PS Ratio falls into.


ROCO:3118
76GF Score
Level Biotechnology Inc ROCO:3118
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Level Biotechnology Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Level Biotechnology's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.869/330.2130*330.2130
=4.869

Current CPI (Mar. 2026) = 330.2130.

Level Biotechnology Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 4.125 241.018 5.652
201609 3.432 241.428 4.694
201612 4.530 241.432 6.196
201703 3.611 243.801 4.891
201706 4.848 244.955 6.535
201709 3.703 246.819 4.954
201712 5.590 246.524 7.488
201803 3.770 249.554 4.989
201806 4.667 251.989 6.116
201809 4.926 252.439 6.444
201812 5.924 251.233 7.786
201903 4.244 254.202 5.513
201906 4.911 256.143 6.331
201909 4.738 256.759 6.093
201912 5.693 256.974 7.316
202003 4.113 258.115 5.262
202006 5.154 257.797 6.602
202009 4.961 260.280 6.294
202012 6.425 260.474 8.145
202103 4.969 264.877 6.195
202106 5.597 271.696 6.802
202109 5.363 274.310 6.456
202112 4.848 278.802 5.742
202203 3.570 287.504 4.100
202206 4.684 296.311 5.220
202209 4.332 296.808 4.820
202212 5.593 296.797 6.223
202303 4.414 301.836 4.829
202306 5.025 305.109 5.438
202309 5.009 307.789 5.374
202312 5.779 306.746 6.221
202403 5.462 312.332 5.775
202406 5.176 314.175 5.440
202409 5.605 315.301 5.870
202412 6.248 315.605 6.537
202503 5.437 319.799 5.614
202506 5.274 322.561 5.399
202509 6.114 324.800 6.216
202512 5.734 324.054 5.843
202603 4.869 330.213 4.869

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$23.63 mean?
Level Biotechnology (ROCO:3118) has a Cyclically Adjusted Revenue per Share of NT$23.63 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Level Biotechnology and its competitors.
Is Level Biotechnology's Cyclically Adjusted Revenue per Share too high?
Level Biotechnology's current Cyclically Adjusted Revenue per Share is NT$23.63. Overall, Level Biotechnology has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Level Biotechnology's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Level Biotechnology's Cyclically Adjusted Revenue per Share of NT$23.63 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Level Biotechnology and its competitors. Level Biotechnology's current Cyclically Adjusted Revenue per Share is NT$23.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Level Biotechnology (ROCO:3118) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.87, compared to a current price of NT$32.10 — trading 5.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$23.63. Level Biotechnology's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Level Biotechnology (ROCO:3118), the current Cyclically Adjusted Revenue per Share is NT$23.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Level Biotechnology (ROCO:3118) Overvalued in 2026?

Based on GuruFocus' analysis, Level Biotechnology stock appears to be undervalued. The current stock price of NT$32.10 is trading 5.2% below its estimated GF Value™ of NT$33.87. GuruFocus considers Level Biotechnology to be Fairly Valued.

Key valuation signals for ROCO:3118:

  • Cyclically Adjusted Revenue per Share: NT$23.63
  • GF Value™: NT$33.87 vs. price of NT$32.10 (5.2% below fair value)
  • GF Score™: 76/100 with 2 warning signs

No single metric tells the full story. See the ROCO:3118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Level Biotechnology Business Description

Address No. 80, Lane 169, Kangning Street, Xizhi District, New Taipei City, TWN, 221
Level Biotechnology Inc is a Taiwan-based company engaged in the sales of biomedical products and providing preclinical testing services. The company has three reportable segments: Department A and B, Department C, and Department D. Department A and Department B sell the cell culture consumables and the antibody reagents, Department C sells the instruments and equipment, and Department D provides CRO services. The majority of revenue is derived from the Department A and B.
76GF Score

Get the complete analysis for ROCO:3118

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.10
Price
NT$33.87
GF Value